Revolution Medicines Stock

revolutionmedicines.comHealthcareFounded: 2014Funding to Date: $226MM

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients.

Register for Details

For more details on financing and valuation for Revolution Medicines, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Revolution Medicines.

Register Today

Team

Management Team

Mark Goldsmith Ph.D
President, Chief Executive Officer and Board Member
Martin Burke MD
Scientific Advisory Board Chairman & Co-Founder
Kevan Shokat Ph.D
Co-Founder & Chief Advisory Board Member
Steve Kelsey MD
President, Research & Development
Margaret Horn JD
Chief Operating Officer
Michael Fischbach Ph.D
Co-Founder & Scientific Advisory Board Member

Board Members

Alexis Borisy
Third Rock Ventures
Kevan Shokat Ph.D
Michael Fischbach Ph.D
Barbara Weber MD
Third Rock Ventures
Martin Burke MD
Vincent Miller MD
Elizabeth Anderson
Laurence Lasky Ph.D
The Column Group
Thilo Schroeder Ph.D
Nextech Invest

Other companies like Revolution Medicines in the Healthcare sector

Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$4.8B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM

News

REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public...
The RAS family of proteins is one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines
Revolution Medicines, Inc., a Redwood City, Calif.-based clinical-stage leader in the discovery and development of novel small molecule inhibitors of frontier oncology targets within notorious pathways, closed a $100m Series C equity financing